Uploaded June 2026 | Updated September 2026, 3 weeks ago
GLP-1 medications like Ozempic and tirzepatide are everywhere right now, but most of what you’re hearing barely scratches the surface of what this class of peptides can actually do. In this episode, Dr. Aaron Hartman shares what 20 years of clinical experience with GLP-1s has taught him about their safety, their surprising range of uses, and why starting doses matter far more than most prescribers acknowledge.
---
📖 UnCURABLE: From Hopeless Diagnosis to Defying All Odds
For everyone medicine has let down → UnCurableBook.com
---
Dr. Hartman traces the science of GLP-1s back to 1902 and walks through the evolution from Byetta to semaglutide to tirzepatide, including what makes each one different and why the newest triple agonist retatrutide deserves careful attention before widespread use. Beyond diabetes and weight loss, he covers FDA-approved and emerging applications including cardioprotection, kidney protection, sleep apnea, and neuroinflammatory conditions, with a particular focus on how microdosing is showing promise in patients with mast cell activation, POTS, and dysautonomia. He also introduces his five-type framework for understanding obesity and explains why GLP-1s address three of those root causes while always needing to rest on top of solid lifestyle foundations.
This is Part 2 of 4, Part 1 covers what peptides are and how they’re regulated; Part 3 covers Thymosin Alpha-1, TB4, BPC-157, and additional popular peptides.
---
ABOUT AARON HARTMAN, MD
Aaron Hartman, MD is a triple-board-certified physician, bestselling author of UnCURABLE: From Hopeless Diagnosis to Defying All Odds, and founder of Richmond Integrative & Functional Medicine. Dr. Hartman is known as the champion of the medically abandoned, helping people once labeled “uncurable” find REAL health and hope through the body’s natural abilities to heal and repair.
AaronHartmanMD.com
GLP-1 medications like Ozempic and tirzepatide are everywhere right now, but most of what you’re hearing barely scratches the surface of what this class of peptides can actually do. In this episode, Dr. Aaron Hartman shares what 20 years of clinical experience with GLP-1s has taught him about their safety, their surprising range of uses, and why starting doses matter far more than most prescribers acknowledge.
---
📖 UnCURABLE: From Hopeless Diagnosis to Defying All Odds
For everyone medicine has let down → UnCurableBook.com
---
Dr. Hartman traces the science of GLP-1s back to 1902 and walks through the evolution from Byetta to semaglutide to tirzepatide, including what makes each one different and why the newest triple agonist retatrutide deserves careful attention before widespread use. Beyond diabetes and weight loss, he covers FDA-approved and emerging applications including cardioprotection, kidney protection, sleep apnea, and neuroinflammatory conditions, with a particular focus on how microdosing is showing promise in patients with mast cell activation, POTS, and dysautonomia. He also introduces his five-type framework for understanding obesity and explains why GLP-1s address three of those root causes while always needing to rest on top of solid lifestyle foundations.
This is Part 2 of 4, Part 1 covers what peptides are and how they’re regulated; Part 3 covers Thymosin Alpha-1, TB4, BPC-157, and additional popular peptides.
---
ABOUT AARON HARTMAN, MD
Aaron Hartman, MD is a triple-board-certified physician, bestselling author of UnCURABLE: From Hopeless Diagnosis to Defying All Odds, and founder of Richmond Integrative & Functional Medicine. Dr. Hartman is known as the champion of the medically abandoned, helping people once labeled “uncurable” find REAL health and hope through the body’s natural abilities to heal and repair.
AaronHartmanMD.com
